NASDAQ:ADMP

Adamis Pharmaceuticals - ADMP Stock Forecast, Price & News

$0.27

0.00 (0.00%)

(As of 09/27/2022 03:59 PM ET)

Add

Compare

Today's Range: $0.24
▼
$0.27
50-Day Range: $0.24
▼
$0.48
52-Week Range: $0.18
▼
$1.48

Volume: 47,607 shs
Average Volume: 712,012 shs
Market Capitalization: $40.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Adamis Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.50% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.14
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.18) to ($0.08) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.17 out of 5 stars

Medical Sector

1061st out of 1,071 stocks

Pharmaceutical Preparations Industry

523rd out of 531 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Adamis Pharmaceuticals.

4.0

Short Interest

Percentage of Shares Shorted
2.50% of the outstanding shares of Adamis Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Adamis Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
Change versus previous month
Short interest in Adamis Pharmaceuticals has recently decreased by 19.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Adamis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Adamis Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADMP.

1.7

News and Social Media Coverage

News Sentiment
Adamis Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Adamis Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 4 people have added Adamis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adamis Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Adamis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 8.58% of the stock of Adamis Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Adamis Pharmaceuticals are expected to grow in the coming year, from ($0.18) to ($0.08) per share.
Price to Book Value per Share Ratio
Adamis Pharmaceuticals has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adamis Pharmaceuticals (NASDAQ:ADMP) Stock

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Stock News Headlines

September 25, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)

September 23, 2022 | seekingalpha.com

ADMP Adamis Pharmaceuticals Corporation

September 21, 2022 | seekingalpha.com

Adamis says Phase 2/3 trial for COVID-19 therapy did not reach main goal

September 21, 2022 | marketwatch.com

Adamis Pharmaceuticals Sink to New Lows After Study Failure >ADMP

September 21, 2022 | finance.yahoo.com

Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy

September 21, 2022 | marketwatch.com

Adamis Ends Tempol Covid-19 Study After Main Endpoint Missed >ADMP

September 21, 2022 | finance.yahoo.com

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

September 12, 2022 | finance.yahoo.com

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

August 30, 2022 | thestreet.com

Adamis Pharmaceuticals Corporation

August 12, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

August 11, 2022 | seekingalpha.com

Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript

August 10, 2022 | apnews.com

Adamis: Q2 Earnings Snapshot

August 10, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

July 29, 2022 | finance.yahoo.com

Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting

June 17, 2022 | morningstar.com

Adamis Pharmaceuticals Corp - Stock Quote ADMP

May 31, 2022 | finance.yahoo.com

What Makes Adamis (ADMP) a New Buy Stock

May 26, 2022 | finance.yahoo.com

Adamis Appoints Vickie Reed to Board of Directors

May 18, 2022 | seekingalpha.com

Adamis Pharmaceuticals names co-founder David Marguglio as CEO

May 18, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

May 17, 2022 | seekingalpha.com

Adamis Pharma stock falls 9% despite better-than expected Q1 revenue

May 17, 2022 | seekingalpha.com

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | seekingalpha.com

Adamis Pharmaceuticals reports Q1 results

May 16, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Company Calendar

Last Earnings: 8/10/2022
Today: 9/27/2022
Next Earnings (Estimated): 11/28/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADMP
CUSIP: N/A
CIK: 887247
Web: www.adamispharmaceuticals.com
Phone: (858) 997-2400
Fax: N/A
Employees: 116
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,830,000.00
Net Margins: N/A
Pretax Margin: -4,288.86%
Return on Equity: -151.88%
Return on Assets: -96.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.58
Quick Ratio: 1.53

Sales & Book Value

Annual Sales: $2.21 million
Price / Sales: 18.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 1.59

Miscellaneous

Outstanding Shares: 149,980,000
Free Float: 141,134,000
Market Cap: $40.49 million
Optionable: Optionable
Beta: 1.02

Key Executives

Mr. David J. Marguglio (Age 52)
Co-Founder, CEO, Pres & Director
Comp: $490.68k

Dr. Ronald B. Moss M.D. (Age 61)
Chief Medical Officer
Comp: $693.2k

Mr. David C. Benedicto (Age 61)
Chief Financial Officer

Ms. Karen K. Daniels (Age 69)
VP of Operations

Mr. Mark Flather
Sr. Director of Investor Relations & Corp. Communications

Ms. Jennifer C. Suski
Sr. Director of Marketing

Mr. Eddie Wabern Glover (Age 72)
Chief Exec. Officer of US Compounding Inc

Mr. Robert B. Rothermel (Age 78)
Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADMP Stock - Frequently Asked Questions

Should I buy or sell Adamis Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View ADMP analyst ratings or view top-rated stocks.
How have ADMP shares performed in 2022?: Adamis Pharmaceuticals' stock was trading at $0.6050 on January 1st, 2022. Since then, ADMP stock has decreased by 58.6% and is now trading at $0.2502.
View the best growth stocks for 2022 here.
When is Adamis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ADMP earnings forecast.
How were Adamis Pharmaceuticals' earnings last quarter?: Adamis Pharmaceuticals Co. (NASDAQ:ADMP) posted its quarterly earnings data on Wednesday, August, 10th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.02. The specialty pharmaceutical company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $1.02 million.
What other stocks do shareholders of Adamis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?: Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
Who are Adamis Pharmaceuticals' major shareholders?: Adamis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends.
How do I buy shares of Adamis Pharmaceuticals?: Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adamis Pharmaceuticals' stock price today?: One share of ADMP stock can currently be purchased for approximately $0.25.
How much money does Adamis Pharmaceuticals make?: Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $37.52 million and generates $2.21 million in revenue each year.
How many employees does Adamis Pharmaceuticals have?: The company employs 116 workers across the globe.
How can I contact Adamis Pharmaceuticals?: Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com.

This page (NASDAQ:ADMP) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adamis Pharmaceuticals - ADMP Stock Forecast, Price & News

Adamis Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows